Full TitleA Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients with Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find the highest dose of the investigational immunotherapy drug cevostamab that can be given safely in people with multiple myeloma that has come back or continued to grow despite treatment which included a medication that targets a protein on myeloma cells called BCMA. Cevostamab attaches to proteins on all myeloma cells and also helps the immune system identify and destroy these cells. It is given intravenously (by vein).
To be eligible for this study, patients must meet several requirements, including:
- Participants must have multiple myeloma that has come back or continued to grow despite treatment that included a medication that targets a protein called BCMA.
- At least 4 weeks must pass since the completion of prior therapies and receipt of the study treatment.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Lesokhin at 646-608-3717.